Evaluating the quality of real-world data on adherence to oral endocrine therapy in breast cancer patients: How real is real-world data?

dc.contributor.author
Navarro-Sabaté, Aurea
dc.contributor.author
Font, R.
dc.contributor.author
Espinàs, Josep Alfons
dc.contributor.author
Solà, J.
dc.contributor.author
Martínez-Soler, Fina
dc.contributor.author
Gil-Gil, Miguel J.
dc.contributor.author
Viñas, Gemma
dc.contributor.author
Tibau, Ariadna
dc.contributor.author
Borrell, M.
dc.contributor.author
Seguí, Miquel A.
dc.contributor.author
Margeli, Mireia
dc.contributor.author
Servitja Tormo, Sonia
dc.contributor.author
Pérez, Cristina
dc.contributor.author
Domenech, Montserrat
dc.contributor.author
Nava, Maria Angeles
dc.contributor.author
Marin, M.
dc.contributor.author
González, Sonia
dc.contributor.author
Borràs, Josep M.
dc.date.accessioned
2025-10-25T07:20:59Z
dc.date.available
2025-10-25T07:20:59Z
dc.date.issued
2025-10-24T12:38:01Z
dc.date.issued
2025-10-24T12:38:01Z
dc.date.issued
2025
dc.date.issued
2025-10-24T12:38:00Z
dc.identifier
Navarro-Sabaté A, Font R, Espinàs JA, Solà J, Martínez-Soler F, Gil-Gil M, Viñas G, Tibau A, Borrell M, Segui M, Margelí M, Servitja S, Perez C, Domenech M, Nava M, Marin M, Gonzalez S, Borràs JM. Evaluating the quality of real-world data on adherence to oral endocrine therapy in breast cancer patients: How real is real-world data? Cancers (Basel). 2025 Jan 9;17(2):200. DOI: 10.3390/cancers17020200
dc.identifier
2072-6694
dc.identifier
http://hdl.handle.net/10230/71647
dc.identifier
http://dx.doi.org/10.3390/cancers17020200
dc.identifier.uri
https://hdl.handle.net/10230/71647
dc.description.abstract
Purpose: The aim of this study was to compare estimates of adherence to oral endocrine therapy (OET) based on real-world data (RWD) and on clinical evaluation in people diagnosed with breast cancer in the public healthcare system in Catalonia (Spain). Methods: We conducted two retrospective cohort studies. Cohort 1 (RWD) consisted of women diagnosed with breast cancer in 2021 in the public healthcare system of Catalonia (Spain). Sources of RWD were the pharmacy billing register, hospital discharge records, and the Catalan health division's central insurance registry. Nonadherence was defined as below 80% adherence in the first year of treatment. Data for cohort 2 came from two population-based cancer registries in Girona and Tarragona (Catalonia), with diagnoses from 2007 to 2011. We evaluated the impact of variables missing from RWD, such as stage and hormonal status. Analyses were performed using a chi-square test and logistic regression, with results stratified by age group and drug type. Results: Nonadherence at one year was 10.9% in cohort 1 and 11.3% in cohort 2. When we reviewed the medical records of a selection of nonadherent women from cohort 1, we found only 59.4% had documented treatment interruptions. Reasons for interruptions in the patients from RWD cohort included adverse effects (48.8%), patient decision (40.0%), medical reasons (29.4%), and other clinical causes (14.7%). Women aged under 50 years and those receiving tamoxifen or a sequential regimen had lower adherence. Determinants associated with nonadherence were similar in both approaches used. Conclusions: This study confirms the validity of estimating adherence with RWD from the Spanish national health system, although when combined with reviewing medical records, this may provide more reliable and higher-quality data. The RWD method provides valuable evidence to help oncologists discuss adherence with their patients.
dc.format
application/pdf
dc.format
application/pdf
dc.language
eng
dc.publisher
MDPI
dc.relation
Cancers. 2025;17(2):200
dc.rights
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Adherence validation
dc.subject
Breast cancer
dc.subject
Oral endocrine therapy
dc.subject
Real-world-data
dc.title
Evaluating the quality of real-world data on adherence to oral endocrine therapy in breast cancer patients: How real is real-world data?
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)